OTCMKTS:UCBJY UCB (UCBJY) Stock Price, News & Analysis → Man Who Predicted 2008: “This Will be Worse.” (From Altimetry) (Ad) Free UCBJY Stock Alerts $65.26 +0.33 (+0.51%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$65.06▼$65.5350-Day Range$49.66▼$64.9352-Week Range$34.85▼$65.55Volume5,933 shsAverage Volume12,120 shsMarket CapitalizationN/AP/E Ratio85.48Dividend Yield0.54%Price TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartDividendFinancialsSEC FilingsShort InterestStock AnalysisAnalyst ForecastsChartDividendFinancialsSEC FilingsShort Interest Get UCB alerts: Email Address Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About UCB Stock (OTCMKTS:UCBJY)UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.Read More UCBJY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart UCBJY Stock News HeadlinesApril 18, 2024 | americanbankingnews.comUCB (OTCMKTS:UCBJY) Stock Price Passes Above 50-Day Moving Average of $57.90December 29, 2023 | seekingalpha.comDrugmakers reportedly planning to raise prices on 500+ drugs in January (update)April 23, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. December 29, 2023 | msn.comDrugmakers reportedly planning to raise prices on 500+ drugs in JanuaryDecember 28, 2023 | msn.comFDA’s new drug approvals for 2023 rise 51% from last yearDecember 1, 2023 | finance.yahoo.comUCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual MeetingNovember 14, 2023 | finance.yahoo.comUCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque PsoriasisOctober 18, 2023 | msn.comFDA approves UCB's Bimzelx for plaque psoriasisApril 23, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. October 4, 2023 | benzinga.comUCB presents late-breaking posters at Child Neurology Society MeetingSeptember 15, 2023 | msn.comEMA advisors recommend many new meds at latest meetingAugust 31, 2023 | markets.businessinsider.comSkin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst AssertsAugust 26, 2023 | msn.comCrohn's disease drugmakers set to benefit from expected rise in casesApril 13, 2023 | msn.comUCB (UCBJY) Declares $0.73 DividendApril 6, 2023 | wsj.comUnited Commercial Bank Ltd.March 20, 2023 | benzinga.comBimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 WeeksDecember 23, 2022 | finance.yahoo.comUCB SA (UCBJY) Stock Historical Prices & Data - Yahoo FinanceDecember 9, 2022 | seekingalpha.comUCB drug meets main goals of 2 phase 3 trials for painful skin disorderNovember 8, 2022 | benzinga.comUCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022September 24, 2022 | benzinga.comUCB presents latest data from generalized myasthenia gravis portfolio at AANEM meetingSeptember 22, 2022 | finance.yahoo.comUCB SA (UCB.BR)September 17, 2022 | reuters.comUCB.BR - UCB SA | Stock Price & Latest News | ReutersSeptember 2, 2022 | benzinga.comUCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV CongressMay 11, 2022 | finance.yahoo.comUCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravisMay 4, 2022 | markets.businessinsider.comJAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA® (fenfluramine) Oral Solution in Lennox-Gastaut Syndrome (LGS)March 29, 2022 | markets.businessinsider.comFINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)March 28, 2022 | finance.yahoo.comUCB's Rare Childhood Epilepsy Drug Scores FDA ApprovalSee More Headlines Receive UCBJY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for UCB and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/23/2024Ex-Dividend for 5/15 Dividend4/26/2024Dividend Payable5/15/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:UCBJY CUSIPN/A CIK1290640 Webwww.ucb.com Phone(322) 559-9999FaxN/AEmployees8,450Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio85.48 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Jean-Christophe Tellier (Age 65)CEO & Executive Director Comp: $4.36MMs. Sandrine Dufour CFA (Age 58)Executive VP, CFO & Chief Corporate Development Dr. Kirsten Lund-Jurgensen Ph.D. (Age 64)Executive Vice President of Supply & Technology Solutions Dr. Dhavalkumar D. Patel M.D. (Age 63)Ph.D., Executive VP & Chief Scientific Officer Ms. Denelle J. Waynick Johnson J.D. (Age 57)Executive VP & General Counsel Mr. Jean-Luc Fleurial (Age 59)Executive VP & Chief Human Resources Officer Prof. Iris Low-Friedrich (Age 64)Executive VP & Chief Medical Officer Mr. Emmanuel Caeymaex (Age 55)Executive VP of Immunology Solutions & Head of US Ms. Caroline VancoillieChief Accounting Officer, Head of Group Finance & CFO of Patient Value FunctionsAntje WitteHead of Investor RelationsMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors UCBJY Stock Analysis - Frequently Asked Questions Should I buy or sell UCB stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for UCB in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" UCBJY shares. View UCBJY analyst ratings or view top-rated stocks. How have UCBJY shares performed in 2024? UCB's stock was trading at $43.60 at the beginning of the year. Since then, UCBJY stock has increased by 49.7% and is now trading at $65.26. View the best growth stocks for 2024 here. Are investors shorting UCB? UCB saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 200 shares, a decline of 71.4% from the March 15th total of 700 shares. Based on an average daily volume of 13,300 shares, the days-to-cover ratio is presently 0.0 days. View UCB's Short Interest. How often does UCB pay dividends? What is the dividend yield for UCB? UCB declared a dividend on Friday, April 19th. Shareholders of record on Monday, April 29th will be paid a dividend of $0.4574 per share on Wednesday, May 15th. This represents a dividend yield of 0.71%. The ex-dividend date is Friday, April 26th. Read our dividend analysis for UCBJY. Is UCB a good dividend stock? UCB (OTCMKTS:UCBJY) pays an annual dividend of $0.36 per share and currently has a dividend yield of 1.26%. The dividend payout ratio is 46.55%. This payout ratio is at a healthy, sustainable level, below 75%. Read our dividend analysis for UCBJY. How do I buy shares of UCB? Shares of UCBJY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:UCBJY) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeHow to camouflage a factory of 53,000 workersStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UCB SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
